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ABSTRACT
Background. Peritoneal dissemination is one of the major
recurrence patterns in patients with pancreatic ductal ade-
nocarcinoma (PDAC) and is associated with poor
prognosis. Here, we assessed the diagnostic potential of
microRNA (miRNA) profiles in peritoneal washings for
prediction of peritoneal dissemination in PDAC.
Patients and Methods. From January 2016 to July 2017,
peritoneal washings were obtained prospectively from 59
patients with PDAC undergoing surgery the Yokohama
City University Hospital. MiRNA expression was evalu-
ated by Agilent human miRNA microarray and quantitative
reverse-transcription polymerase chain reaction.
Results. Microarray analysis identified upregulated and
downregulated miRNAs in peritoneal washings of patients
with peritoneal dissemination. We validated four miRNAs
(miR-141-3p, miR-194-3p, miR-194-5p, and miR-200c-3p)
with high expression in peritoneal washings. The cumula-
tive incidence rate of peritoneal recurrence in peritoneal
cytology-negative patients in the miR-194-5p high group
was significantly higher than that in the miR-194-5p low
group (p = 0.002). Univariate and multivariate analyses
revealed that high miR-194-5p was associated with overall
survival (OS).
Conclusions. High expression of miR-194-5p in peri-
toneal washings is associated with peritoneal recurrence
and poor OS in patients with peritoneal cytology-negative
PDAC.
Pancreatic ductal adenocarcinoma (PDAC) is a rare
cancer for which no significant improvements in diagnosis
and therapy have been made in the last 30 years. Despite
considerable progress in understanding of the disease at the
molecular level, novel findings have not yet translated into
clinical benefits, and most patients still face a grim median
survival of 5–6 months. With over 43,000 PDAC-related
deaths in the USA in 2017 and over 42,000 in Europe in
2016, this malignancy is currently the fourth leading cause
of cancer-related death and is predicted to become the
second by 2030.1–3 Peritoneal dissemination of pancreatic
cancer poses significant difficulties for both patients and
clinicians because the associated poor general condition of
affected patients and problems in assessing scattered
tumors, due to ascites, jaundice, and ileus, hamper
administration of standard treatment. Peritoneal recurrence
of pancreatic cancer is one of the major common recur-
rence patterns according to previous reports.4–7
In some types of cancer, such as ovarian and gastric
cancer, which are known to have a high rate of postoper-
ative peritoneal recurrence, peritoneal wash cytology (CY)
is often used to predict risk of peritoneal dissemination.8,9
However, the prognostic significance of CY positivity in
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potentially resectable pancreatic cancer is controversial.
Some studies have reported that CY positivity without
distant metastasis should not preclude resection in
resectable patients with pancreatic cancer and that, in these
cases, long-term survival is possible after adjuvant
chemotherapy.10–12 In contrast, several other studies have
shown that patients with CY (?) status are associated with
advanced disease and poor prognosis and have survival
rates equivalent to those of other stage IV diseases.7,13–16
We previously reported that high expression of MUC1 in
peritoneal washings is a significant risk factor for peri-
toneal recurrence after R0 resection of CY (-) PDAC.17
However, the predictive power of MUC1 may be limited,
as univariate analysis was performed in that previous study.
Therefore, better prognostic predictors in pancreatic cancer
are needed.
MicroRNAs (miRNAs) are small noncoding RNAs with
length of 20–23 nucleotides;18 they regulate the expression
of more than 30% of human genes and therefore play key
roles in many biological functions.19 A number of miRNAs
have been reported as predictors of clinical outcome in
pancreatic adenocarcinoma;20 For example, miR-21 and
miR-1225-5p may serve as biomarkers of peritoneal
recurrence after curative gastric cancer resection.21 How-
ever, no studies have identified relevant miRNAs in
peritoneal washings as biomarkers of peritoneal recurrence
of any abdominal cancer. The purpose of this study is to
identify highly expressed miRNAs in cases of peritoneal
dissemination and investigate whether they are associated
with peritoneal recurrence after resection.
PATIENTS AND METHODS
Ethics Committee Approval
The study protocol was approved by the Institutional
Ethical Committee at the Yokohama City University
(Yokohama, Japan; B111110029); written informed con-
sent was obtained from all patients prior to enrollment in
the study.
Clinical Samples
From January 2016 to July 2017, peritoneal washings
were obtained prospectively from 63 patients with preop-
erative diagnosis of pancreatic cancer undergoing surgery
at Yokohama City University Hospital. Four patients
diagnosed with intraductal papillary–mucinous carcinoma
after surgery were excluded from the study.
We poured 600 mL of saline into the right upper
abdomen, left upper abdomen, and pelvis during laparo-
tomy and collected 300 mL of total peritoneal lavage fluid
from each site. Half of this fluid was used for routine CY
examination, while the remaining half was used for quan-
titative polymerase chain reaction (qPCR) evaluation. In all
cases, we obtained peritoneal washings at the beginning of
surgery to avoid blood cell contamination. qPCR results
were not used for therapeutic decision-making for any
patient.
Follow-up data were obtained from patients’ medical
records. To confirm no recurrence, physical examination
and laboratory investigations, including tests for tumor
markers, were performed every month, and computed
tomography (CT) scanning was performed every 3 months.
If we could not diagnose recurrence through CT scanning
despite findings suggesting recurrence (such as an increase
in the levels of tumor markers), we performed positron
emission tomography-CT (PET-CT). The gold standard for
diagnosing peritoneal recurrence is positive CY for ascites
accumulation after surgery. However, even if CY for
ascites was not performed, peritoneal dissemination nod-
ules were detected using CT or PET-CT. Severity of
postoperative complications was graded according to the
Clavien–Dindo system.22,23
Total RNA Extraction
Total RNAs (including miRNA) from peritoneal wash-
ings were extracted using an miRNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
instructions and stored at - 80 C until further analysis.
MiRNA Microarray
MiRNAs extracted from the five peritoneal washing
samples were analyzed using Agilent Human miRNA
Microarrays (Santa Clara, CA, USA). Cyanine-3 (Cy3)-
labeled miRNA was prepared from 100 ng total RNA using
the miRNA Complete Labeling and Hyb Kit (Agilent)
according to the manufacturer’s instructions. The Cy3-la-
beled miRNA was resuspended in 18 lL of nuclease-free
water, and 4.5 lL of 109 GE Blocking Agent and 22.5 lL
of 2 9 Hi-RPM Hybridization Buffer were added, fol-
lowing the manufacturer’s instructions. After the sample
had been incubated at 100 C for 5 min, it was immedi-
ately transferred to an ice–water bath for 5 min and
hybridized to Human miRNA Microarray Kit 8 9 60 K
rel.21.0 (Agilent) for 20 h at 55 C in an Agilent rotating
hybridization oven. After hybridization, microarrays were
washed for 5 min at 20–25 C with GE wash buffer 1
(Agilent) and 5 min with 37 C GE wash buffer 2 (Agi-
lent), then dried. Microarrays were scanned immediately
after washing on an Agilent SureScan Microarray Scanner
(G2600D) using the one-color scan setting for 8 9 15 k
array slides (scan area 61 9 21.6 mm2, scan resolution 5
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lm; dye channel set to green; green PMT set to XDR Hi
100% and XDR Lo 5%). The scanned images were ana-
lyzed with Feature Extraction Software 12.0.3.1 (Agilent)
using default parameters to obtain background-subtracted
and spatially detrended processed signal intensities. The
GeneView files were generated using Feature Extraction
Software.
qPCR
Peritoneal washings were centrifuged at 2000 rpm for
10 min with MX300 (TOMY SEIKO, Japan), and the
supernatant was removed. After addition of 1 mL of
phosphate-buffered saline, the specimens were centrifuged
again at 10,000 rpm for 5 min at 4 C. Total RNA was
extracted from the remaining pellet after homogenization
with QIAzol (Qiagen), followed by on-column clean up
with the miRNeasy Mini Kit (Qiagen). Reverse transcrip-
tion (RT) was performed using 2 lL of RNA template per
10 lL of RT reaction with the Universal cDNA Synthesis
Kit II (Exiqon, Vedbaek, Denmark).
Four microliters of complementary DNA (cDNA) was
used to amplify has-miR-194-3p, has-miR-194-5p, has-
miR-141-3p, has-miR-200c-3p, has-miR-28-3p, has-miR-
3663-5p, has-mR-4446-3p, has-miR-3121-3p, has-miR-
8485, and has-miR-26b-5p endogenous control, using the
miRCURY LNATM miRNA PCR Assays system (Qiagen),
in a final volume of 10 lL. The qPCR master mix con-
tained 80-fold-diluted cDNA and 1 9 ExiLENT SYBR
green master mix (Exiqon #203403). All reactions were
performed in triplicate with the ABI 7900HT Fast Real-
Time PCR System (Applied Biosystems, Foster City, CA,
USA), and the mean values were analyzed to prevent dis-
persion of results. Relative quantification of miRNA
expression was calculated using the 2-DDCt method.24
Statistical Analysis
Data were analyzed using SPSS version 25 for Windows
(SPSS, Chicago IL, USA). For univariate analysis, bino-
mial variables were compared using the v2 test. Continuous
variables were compared using the Mann–Whitney U test.
The continuous variables selected based on univariate
analysis were converted to dichotomous variables using
receiver operating characteristic (ROC) curve analysis.
Multivariate survival analyses were performed by Cox
proportional hazards regression. Significant parameters on
univariate analyses were included in multivariate analyses
for overall survival (OS). The cumulative incidence rate of
peritoneal dissemination recurrence was estimated (instead
of Kaplan–Meier estimates) because other recurrences
followed by systemic treatment competed with the peri-
toneal dissemination recurrence. Survival curves were
constructed using the Kaplan–Meier method and compared
using the log-rank test. P\ 0.05 was considered
significant.
RESULTS
Identification of Deregulated MiRNA
We first performed miRNA array analysis using samples
from five patients with PDAC to identify differentially
expressed miRNA in patients with peritoneal dissemina-
tion. Three of them had unresectable PDAC because of
peritoneal dissemination, one had peritoneal recurrence
after surgery, and the other was relapse-free after surgery
during the observation period. We compared patients with
unresectable PDAC and peritoneal dissemination and
relapse-free patients, and patients with peritoneal recur-
rence and relapse-free patients and identified upregulated
(fold change[ 1) and downregulated (fold change\- 1)
miRNAs. We selected eight miRNAs (miR-200c-3p, miR-
141-3p, miR-3663-5p, miR-194-3p, miR-194-5p, miR-
4446-3p, miR-3121-3p, and miR-8485, Table 1): five
upregulated miRNAs (miR-200c-3p, miR-141-3p, miR-
3663-5p, miR-194-3p, and miR-194-5p) and three down-
regulated miRNAs (miR-4446-3p, miR-3121-3p, and miR-
8485). In unresectable patients with peritoneal dissemina-
tion versus relapse-free patients, miR-200c-3p (11.5-fold),
miR-141-3p (7.48-fold), miR-3663-5p (5.85-fold), miR-
194-3p (5.22-fold), and miR-194-5p (3.49-fold) were
increased, while miR-4446-3p (3.15-fold), miR-3121-3p
(2.91-fold), and miR-8485 (2.18-fold) were decreased. In
patients with peritoneal recurrence versus relapse-free
patients, miR-3663-5p (5.69-fold), miR-200c-3p (5.22-
fold), miR-194-3p (3.71-fold), miR-141-3p (1.42-fold), and
miR-194-5p (1.1-fold) were increased, while miR-8485
(2.14-fold), miR-4446-3p (1.33-fold), and miR-3121-3p
(1.08-fold) were decreased.
Characteristics of Patients with Pancreatic Cancer
From January 2016 to July 2017, peritoneal washings
were obtained prospectively from 59 patients with PDAC
undergoing surgery at Yokohama City University Hospital.
Radical resection was not performed in 17 patients because
of detection of distant metastatic lesions: seven patients
had liver metastasis, eight had peritoneal dissemination,
and two had paraaortic lymph node metastasis. We rou-
tinely applied CY from 2010 to 2017 in our department,
but CY positivity was observed in only 2 cases of 224
resected cases. Although our institution has a policy of
resection even if the CY from the washing is positive, the
resected cases were all cytologically negative in this study
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period. In other words, of the 42 resected patients included
in this study, CY was negative in all cases, 10 (23.8%) had
peritoneal recurrence and were therefore classified into the
peritoneal recurrence group, while the remaining 32
(76.2%) were classified into the non-peritoneal recurrence
group. In the non-peritoneal recurrence group, 17 patients
experienced recurrence with distant metastasis: seven
patients had metastasis in the liver, five in the lungs, and
two in the paraaortic lymph nodes. Three patients had local
recurrence, while 15 patients did not experience recurrence
within the follow-up period.
For the 42 patients who underwent resection, we
reviewed the demographic information and clinicopatho-
logical characteristics, including tumor size, location, and
grade (Table 2). There were no significant differences in
age, sex, tumor marker level at operation, tumor location,
tumor size, or clinical TNM stage between the peritoneal
recurrence and non-peritoneal recurrence groups. The
proportion of neural invasion (p = 0.083) and vascular
invasion (p = 0.026) was higher in the peritoneal recur-
rence group than in the non-peritoneal recurrence group.
The median observation period after surgery was
19.8 months.
Expression of MiR-141-3p, MiR-194-3p, MiR-194-5p,
and MiR-200c-3p in Peritoneal Washings
Peritoneal washing samples were collected from the 59
patients with PDAC, and the levels of the eight selected
miRNAs were assessed by qRT-PCR. We validated four of
the miRNAs (miR-141-3p, miR-194-3p, miR-194-5p, and
miR-200c-3p).
We then investigated whether these four miRNAs were
associated with peritoneal recurrence after resection. Resected
patients with peritoneal recurrence had higher levels of miR-
141-3p (p = 0.040), miR-194-5p (p = 0.019), and miR-200c-
3p (p = 0.030) than patients with no recurrence or non-peri-
toneal recurrence (Fig. 1).
The cutoff value for the selected continuous variable for
predicting peritoneal recurrence on univariate analysis was
estimated using ROC curves. The best cutoff value was
63.4 for miR-141-3p/miR-26b-5p, 3.11 for miR-194-5p/
miR-26b-5p, and 9.80 for miR-200c-3p/miR-26b-5p. Using
this cutoff value, we converted the quantity of miR-141-3
miR-26b-5p, miR-194-5p/miR-26b-5p, and miR-200c-3p/
miR-26b-5p to a binary variable (high or low). Of the 42
patients, 18 were miR-141-3p high and 24 were miR-141-
3p low, while 16 were miR-194-5p high and 26 were miR-
194-5p low. In the same way, 18 were miR-200c-3p high
and 24 were miR-200c-3p low.
In this study, 28 of 42 patients received neoadjuvant
chemoradiotherapy. Among 17 cases with high miR-194-
5p, 12 received neoadjuvant chemoradiotherapy. Out of 25
cases with low miR-194-5p, 16 received neoadjuvant
chemoradiotherapy. The Chi square test gave a P value of
0.747; That is, no correlation was found between miR-194-
5p expression and neoadjuvant chemoradiotherapy.
Association of MiR-194-5p with Peritoneal Recurrence
and OS
The cumulative incidence rate of peritoneal recurrence
in the miR-194-5p high group was significantly higher than
that in the miR-194-5p low group (p = 0.001). Median
peritoneal recurrence-free survival for the miR-194-5p low
group was 19.0 months. Comparison of OS between the
miR-194-5p high and low groups revealed that OS was
TABLE 1 MiRNAs significantly upregulated and downregulated in PDAC patients based on miRNA microarray
P UR (N = 3) (average) Non rec (N = 1) Fold change [log2] P rec (N = 1) Non rec (N = 1) Fold change [log2]
Upregulated miRNAs
MiR-200c-3p 649.7 0.1 11.50 3.7 0.1 5.22
MiR-141-3p 1198.4 4 7.48 10.8 4 1.42
MiR-3663-5p 7.0 0.1 5.85 5.2 0.1 5.69
MiR-194-3p 4.0 0.1 5.22 1.3 0.1 3.71
MiR-194-5p 745.2 53.3 3.49 114.6 53.3 1.1
Downregulated miRNAs
MiR-4446-3p 5.9 46.4 - 3.15 18.5 46.4 - 1.33
MiR-8485 30.9 121 - 2.18 27.6 121 - 2.13
MiR-3121-3p 2.1 7.6 - 2.91 3.6 7.6 - 1.08
The continuous variable represents the total gene signal
miRNA micro RNA, PDAC pancreatic ductal adenocarcinoma, P UR unresectable with peritoneal dissemination, Non rec relapse-free patients, P
rec patients with peritoneal recurrence
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TABLE 2 Histopathological characteristics of the two groups stratified by peritoneal recurrence status
Variable Peritoneal recurrence group (N = 10) Non-peritoneal recurrence group (N = 32) P value
Age, years 70.5 (58–74) 68 (65.5–74.5) 0.531
Sex
Male 7 17 0.473
Female 3 15
Tumor markers
CEA (ng/mL) 4.1 (3.5–5.6) 3.0 (2.15–4.30) 0.201
CA19-9 (U/mL) 138 (12–182) 24 (12.5–75.0) 0.742
SPan-1 (U/mL) 51 (11–67) 19 (10–32) 0.524
DUPAN-2 (U/mL) 49 (25–430) 58 (25–345) 0.670
Tumor location 0.404
Head 9 23
Body/tail 1 9
Tumor size (cm) 2.7 (2.2–3.7) 2.40 (1.70–2.95) 0.932
Neoadjuvant chemoradiotherapy 0.451
No 2 12
Yes 8 20
Adjuvant chemotherapy 0.657
No 1 5
Yes 9 27
Operative procedures 0.404
PD 9 23
DP/DP-CAR 1 9
UICC T-stage 0.506
T1 0 1
T2 0 0
T3 5 21
T4 5 10
Lymph node metastasis 0.679
Negative 3 18
Positive 7 14
Neural invasion 0.083
No 2 15
Yes 8 17
Vascular invasion 0.026
No 2 21
Yes 8 11
UICC stage 0.665
IA 0 1
IB 0 0
IIA 2 12
IIB 3 8
III 5 11
Continuous variables shown as median (interquartile range)
CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, PD pancreaticoduodenectomy, DP distal pancreatectomy, DP-CAR distal
pancreatectomy with en bloc celiac axis resection
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significantly shorter for the former (p = 0.048; Fig. 2). The
median OS of miR-194-5p high patients was 36.9 months.
Univariate analysis showed that DUPAN-2, miR-194-
5p, and vascular invasion were associated with peritoneal
recurrence. Multivariate analysis showed that miR-194-5p
and vascular invasion were independent factors of peri-
toneal recurrence (Table 3). Additionally, univariate
analysis showed that neoadjuvant chemoradiotherapy,
adjuvant chemotherapy, and miR-194-5p were associated
with OS. Multivariate analysis, miR-194-5p, and adjuvant
chemotherapy were independent factors of OS (Table 3).
DISCUSSION
Unlike previous reports, which assessed the levels of
prognostic biomarkers in pancreatic cancer tissues, this study
focused on detection of factors in peritoneal washings from
patients with PDAC. To discover factors for early peritoneal
recurrence of PDAC, we performed miRNA microarray
analysis and identified three miRNAs that were specifically
downregulated (miR-4446-3p, miR-8485, and miR-3121-3p)
and five that were specifically upregulated (miR-200c-3p,
miR-141-3p, miR-3663-5p, miR-194-3p, and miR-194-5p) in
PDAC patients with peritoneal dissemination. Four of these
miRNAs (miR-200c-3p, miR-141-3p, miR-194-3p, and miR-
194-5p) were validated by qRT-PCR, and one of them (miR-
194-5p) was associated with peritoneal recurrence after radi-
cal resection on Kaplan–Meier analysis and with OS on
univariate and multivariate analyses.
The American Joint Committee on Cancer and treatment
guidelines from the National Comprehensive Cancer Net-
work consider CY (?) as stage IV metastatic cancer and a
contraindicator for pancreatic resection.25,26 However,
many patients develop peritoneal recurrence, despite neg-
ative CY.27 This study showed that miR-194-5p in
peritoneal washings is a significant risk factor for both
peritoneal recurrence and OS.
A study showed that upregulation of miR-194 promotes
tumor growth and progression in PDAC, possibly via
suppression of Dachshund homolog1 (DACH1).28 Simi-
larly, Mees et al.29 reported that upregulation of miR-194
correlates with reduced expression of tumor suppressor
EP300 in metastatic PDAC cells. These findings suggest
that miR-194 plays a favorable role in PDAC progression.
Accordingly, we demonstrated here that high expression of
miR-194-5p is associated with peritoneal recurrence.
MiR-194-5p is associated with epithelial-to-mesenchy-
mal transition (EMT) in gastric cancer,30 and EMT plays a
crucial role in the invasion and metastasis of diverse car-
cinomas, including PDAC.31 EMT is characterized by loss
of epithelial cell-to-cell contacts and acquisition of motile
mesenchymal features by epithelial cells, leading to cell
migration and invasion,32–35 resulting in distant metastasis
and peritoneal dissemination. Based on these findings, we
speculate that miR-194-5p may promote EMT of PDAC
cells and cause peritoneal dissemination.
In the present study, CY was negative in all cases, but
peritoneal recurrence was observed in 10 cases. Nine of
these 10 cases received tegafur/gimeracil/oteracil (S-1;
Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) as adjuvant
chemotherapy. Although 8 of 17 miR-194-5p high patients
had peritoneal recurrence, their survival was significantly
better than that of patients with miR-194-5p high expres-
sion without adjuvant chemotherapy. Also, miR-194-5p
low patients who received adjuvant chemotherapy showed
much higher survival curves than patients with miR-194-5p
low without adjuvant chemotherapy (Supplementary
Fig. 3). There results suggest that S-1 adjuvant therapy has
a role in the improvement of survival. Conroy et al.
reported that adjuvant therapy with a modified FOLFIR-
INOX regimen led to significantly longer survival than
gemcitabine among patients with resected pancreatic can-
cer, but with higher incidence of toxic effects.36
Considering this high toxicity, selection of patients is
TABLE 3 Multivariate
analysis for peritoneal
recurrence and overall survival
Factor Peritoneal recurrence Overall survival
Multivariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
MiR-194-5p expression level 0.010 0.047
Low 1.00 1.00
High 7.792 (1.64–46.99) 3.61 (1.01–12.87)
Vascular invasion 0.040 –
Negative 1.00 –
Positive 5.10 (1.08–24.12) –
Adjuvant chemotherapy – 0.001
Yes – 1.00
No – 10.15 (2.59–39.75)
HR hazard ratio, CI confidence interval
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important, and miR-194-5p in peritoneal washings might
be useful for this purpose. In addition, use of neoadjuvant
therapy for treatment of potentially resectable pancreatic
cancer remains controversial.37–39 In Japan, Motoi et al.
reported neoadjuvant chemotherapy for resectable pancre-
atic cancer in the PREP-01 study.40 We suppose that
neoadjuvant chemotherapy may become more common
even for resectable pancreatic cancer in the near future. We
hope that use of findings of miR-194-5p in peritoneal
washings will be beneficial to improve patients’ survival.
We are currently preparing a prospective study concerning
miR-194-5p in peritoneal washings for future individual-
ized treatment strategies for pancreatic cancer.
Liquid biopsies, a recently adopted term for blood-based
molecular analyses for cancer diagnostics, enables moni-
toring of disease evolution and response to treatment. One
major advantage of liquid biopsies is the ability to compare
serial samples from the same patient and thus generate a
molecular readout of disease progression and therapy
response or resistance in real time. Additionally, blood
collection is minimally invasive and provides a biospeci-
men of comparable composition from a homogeneous
compartment, i.e., the bloodstream.41 Although miR-194-
5p has been reported as a biomarker for osteoporosis and
hepatitis B in liquid biopsies, there are no similar reports
for pancreatic cancer.42,43 In the near future, prediction of
early relapse in patients may be possible by detecting rel-
evant biomarkers in more convenient samples, including
blood.
This study has limitations worth noting. Only a single
institute was included in this retrospective analysis. In
addition, the sample size was small, and the follow-up
period was relatively short. Furthermore, the effect of
neoadjuvant chemotherapy on miRNAs in peritoneal
washings is also unknown. However, this study identified
the possibility that miR-194-5p is associated with not only
peritoneal recurrence but also OS. Further studies on a
larger number of patients with longer follow-up periods are
warranted.
In conclusion, miR-194-5p in peritoneal washings is
associated with peritoneal recurrence and OS in patients
with PDAC and may provide guidance for pancreatic
cancer treatment.
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